Skip to main content
. 2017 Mar 6;8(16):26979–26991. doi: 10.18632/oncotarget.15927

Figure 5. Knock down of PP2A-B55α impairs embryonic development to the blastocyst stage.

Figure 5

(A) Representative images of control and PP2A-B55α-KD blastocysts at 4.5 days. Bar = 50 μm. (B) Endogenous PP2A-B55α mRNA expression levels analyzed by real-time RT-PCR at the blastocyst stage after injection of PP2A-B55α-targeting dsRNA. Expression was normalized to that in the control group. Ppia was used as an internal standard because it was not affected by PP2A-B55α-targeting dsRNA injection. (C) Embryonic development rates in the control and PP2A-B55α-KD groups. (D) The number of cells in blastocysts was determined by counting cells in Hoechst 33342-stained embryos. The numbers of embryos examined in each experimental group are shown in the bars. The data are mean ± SD of three independent experiments. Statistically significant differences are indicated by asterisks (*p < 0.05; **p < 0.01).